All News
Filter News
Found 452 articles
-
Tome Biosciences Acquires Replace Therapeutics
1/2/2024
Tome Biosciences, Inc., the programmable genomic integration company, announces that it has acquired Replace Therapeutics Inc., a private biotechnology company developing a novel PGI method capable of inserting and deleting small DNA sequences.
-
FDA Keynote Speaker in the Spotlight, CAR-T Industry Leaders Gather for Discussion-Join the 2024 GenScript Biotech Global Forum for a New Journey in Cell and Gene Therapy
12/25/2023
The innovative development of biopharmaceuticals has ushered in a new era for disease treatment, bringing unprecedented hope to countless patients.
-
Gene Editing Market Size Expected to Reach USD 29.93 Bn by 2032
12/22/2023
The global gene editing market size is estimated to reach around USD 29.93 billion by 2032, increasing from USD 6.94 billion in 2022.
-
Titans Gather, Future Embarks: The GenScript Biotech Global Forum coinciding with the 2024 J.P. Morgan Healthcare Conference in San Francisco to Convene 20+ KOLs, Exploring Disruptive Transformations and Infinite Opportunities in GCT
12/14/2023
Technological advancements continuously empower the life sciences. Gene and cell therapy, as breakthrough treatments, are turning the once-unreachable dream of curing many diseases into reality.
-
CRISPR & Cas Genes Market Size to Hit USD 14.65 Billion by 2032
12/14/2023
The global CRISPR & Cas genes market size was valued at USD 2.58 billion in 2022 and is projected to surpass around USD 14.65 billion by 2032, expanding at a healthy CAGR of 19% from 2023 to 2032.
-
Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform
12/12/2023
Tome Biosciences, Inc., the programmable genomic integration company, has launched to usher in a new era of genomic medicines based on programmable genomic integration.
-
CRISPR Continuous to Innovate! Exploring the Future of Cell & Gene Therapy, Industry Leaders Converge at the 2024 GenScript Biotech Global Forum
12/7/2023
The rapid advancement of technology has propelled the field of life sciences into unprecedented growth, constantly expanding our understanding and imagination.
-
Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines
12/5/2023
Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful $30 million Series B funding round, led by Sanofi Ventures.
-
Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
11/14/2023
Intellia Therapeutics, Inc. today announced that the European Commission (EC) has granted orphan drug designation to NTLA-2002 for the treatment of hereditary angioedema (HAE).
-
Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
11/9/2023
Intellia Therapeutics, Inc. today reported operational highlights and financial results for the third quarter ended September 30, 2023.
-
Maravai LifeSciences Reports Third Quarter 2023 Financial Results
11/7/2023
Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2023, together with other business updates.
-
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
11/3/2023
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data from its hematology pipeline will be shared in 19 abstracts at the American Society of Hematology (ASH) Annual Meeting from December 9 to 12 in San Diego, CA.
-
Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting
11/2/2023
Intellia Therapeutics, Inc. presented additional interim results from its ongoing Phase 1 study of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin amyloidosis.
-
Regeneron Reports Third Quarter 2023 Financial and Operating Results
11/2/2023
Regeneron Pharmaceuticals, Inc. announced financial results for the third quarter of 2023 and provided a business update.
-
Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November
10/26/2023
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced two upcoming events in November.
-
The trial, which is the first late-stage study of an in vivo CRISPR treatment in the U.S., will start by the end of 2023. Intellia's NTLA-2001 is a treatment candidate for transthyretin amyloidosis cardiomyopathy.
-
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
10/18/2023
Intellia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.
-
Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
10/13/2023
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE).
-
The companies are expanding their long-standing CRISPR/Cas9 gene editing collaboration for the second time, now seeking to target neurological and muscular conditions.
-
Rosalind Franklin University’s 2nd Annual Biomedical Innovation Day Keynote by Biotechnology Industry Leader in CRISPR Gene-editing
10/3/2023
Rosalind Franklin University’s 2nd Annual Biomedical Innovation Day, “Breaking New Ground in Cancer, Immunology and Infection,” will be held virtually and in-person on Oct. 18